Meet the Rare Collective

Together, we provide clients with a senior-level suite of rare disease experts.

Jean Campbell

JF Campbell Consultants
Discipline: Patient Advocacy

Jean is a nationally recognized advocate for patients with rare diseases and a co-founder of Professional Patient Advocates in Life Sciences (PPALS), a non-profit organization committed to supporting the function of patient advocacy within the biotech and pharmaceutical industries.

Prior to starting her own consulting firm, JF Campbell Consultants, Jean worked at the National Organization for Rare Diseases for nearly two decades, generating an impressive record of success in membership development, fundraising and corporate relations.

Jean received her Bachelor of Arts in History from City University of New York, Hunter College and earned a certification in non-profit management from Columbia University Business School in New York.

Patti Engel

Patti Engel, RN, BSN

Engage Health
Discipline: Market Development, Research and Strategy

Patti has helped define the orphan drug market through her work spanning many disciplines and therapeutic areas. Over the course of her career, Patti has introduced successful strategies and created customized tools and data bases to better understand the needs of rare disease communities.

As the principal and founder of Engage Health, Patti brings extensive experience in strategic and infrastructure planning, patient identification and quantification, market research, market valuation, clinical trial recruitment, risk management and managed distribution for orphan drugs and specialty medical products, policy and governmental affairs.

A frequent presenter on complex issues related to commercializing therapies for rare diseases, Patti led marketing and sales at Orphan Medical, Inc., and spent more than a decade in various sales and marketing management roles at 3M Pharmaceuticals. She sits on the advisory board for Raptor Pharmaceuticals, Kakkis EveryLife Foundation, and is a member of the National Organization for Rare Disorder’s Corporate Council Advisory Group and Global Genes’ Corporate Alliance.

David Lapidus

David Lapidus

LapidusData
Discipline: Data Analytics and Modeling

Management teams rely on David to gain a better understanding of epidemiology in rare diseases through his experience in analytics, modeling and forecasting. LapidusData specializes in complex markets with atypical dynamics, such as rare diseases.

As part of cross-functional teams at both Decision Resources and Genzyme, David has analyzed many types of market data to develop tools which achieve strategic objectives. His proprietary models and data collection systems serve as the backbone of commercial infrastructure throughout the product cycle.

David received his Bachelor of Arts in Social Studies from Harvard University and has completed extensive coursework in epidemiology at Tufts University in Massachusetts.

Doug Paul

Doug Paul, PharmD, PhD

MME
Discipline: Price, Reimbursement, and Market Access

As a PhD, Doug is rooted in patient care. A frequent lecturer and trusted advisor on pricing and reimbursement, Doug has developed pricing strategies that reflect the value of therapies. He has worked on a variety of initiatives for pharmaceutical and medical technology companies, including marketing strategy, pricing strategy, pricing research, management/analysis of forecasts, market assessments and product-acquisition assessments.

Doug previously led marketing efforts for a medical device firm and has been active at the national level with multiple pharmacy associations.

Doug received a PharmD and a PhD in pharmaceutical marketing from the University of Mississippi. He currently holds an adjunct appointment as Assistant Professor at the University of Mississippi School of Pharmacy.

Chris Smith

Chris Smith

SmithSolve
Discipline: Corporate Communications and Public Relations

Chris has more than 25 years of experience in healthcare communications, including leadership positions with global pharmaceutical, biotechnology and public relations firms. As an expert in rare disease communication, he knows how to address the scientific, medical, clinical, social and economic aspects of orphan drug development. His work spans more than a dozen biopharma companies, and includes patient advocacy support, patient panels, patient meetups, media relations, investor events, patient days, talent acquisition, clinical trial recruitment, corporate branding and website development, pipeline communications, data announcements, and more. Chris has worked across diverse therapeutic categories and has represented many of the world’s leading healthcare companies, including Alexion, AstraZeneca, Johnson & Johnson, Pfizer and Sanofi.

Chris received his Bachelor of Arts in Communications Studies from Muhlenberg College in Pennsylvania.